Evidence map›Paper›PMID 33472944›Full record

ReviewDiabetes2021

Building Biomimetic Potency Tests for Islet Transplantation.

Aaron L Glieberman, Benjamin D Pope, Douglas A Melton, Kevin Kit Parker

Abstract readReview
In one paragraph

Review in Diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. A Fresh Look at Islet Isolation from Rabbit Pancreases.International journal of molecular sciences · 2024
    Article
  4. Article
  5. Article
  6. Islets-on-Chip: A Tool for Real-Time Assessment of Islet Function Prior to Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aaron L GliebermanDisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA.ORCID 0000-0001-6606-2632
Benjamin D PopeDisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA.ORCID 0000-0003-1847-9163
Douglas A MeltonHarvard Department of Stem Cell and Regenerative Biology, Cambridge, MA.
Kevin Kit ParkerDisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA kkparker@seas.harvard.edu.ORCID 0000-0002-5968-7535

Funding

Production of clinical-grade diabetes patient-specific induced pluripotent stem cell lines intended for autologous beta cell replacement therapyUC4DK104165 · NIDDK · HARVARD UNIVERSITY · PI MELTON, DOUGLAS A · 2014 to 2017
$7.3M
NIDDK NIH HHS UC4 DK104165
6 · The paper itself

Abstract

Diabetes is a disease of insulin insufficiency, requiring many to rely on exogenous insulin with constant monitoring to avoid a fatal outcome. Islet transplantation is a recent therapy that can provide insulin independence, but the procedure is still limited by both the availability of human islets and reliable tests to assess their function. While stem cell technologies are poised to fill the shortage of transplantable cells, better methods are still needed for predicting transplantation outcome. To ensure islet quality, we propose that the next generation of islet potency tests should be biomimetic systems that match glucose stimulation dynamics and cell microenvironmental preferences and rapidly assess conditional and continuous insulin secretion with minimal manual handing. Here, we review the current approaches for islet potency testing and outline technologies and methods that can be used to arrive at a more predictive potency test that tracks islet secretory capacity in a relevant context. With the development of potency tests that can report on islet secretion dynamics in a context relevant to their intended function, islet transplantation can expand into a more widely accessible and reliable treatment option for individuals with diabetes.

Indexed as

BiomimeticsDiabetes Mellitus, Type 1HumansInsulinInsulin SecretionIslets of Langerhans TransplantationInsulin

Identifiers

PMID33472944
PMCPMC7881865

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.